Nothing Special   »   [go: up one dir, main page]

LT3334747T - Įkrautas giluminis antigeną surišančio baltymo filtravimas - Google Patents

Įkrautas giluminis antigeną surišančio baltymo filtravimas

Info

Publication number
LT3334747T
LT3334747T LTEPPCT/US2016/046929T LTUS2016046929T LT3334747T LT 3334747 T LT3334747 T LT 3334747T LT US2016046929 T LTUS2016046929 T LT US2016046929T LT 3334747 T LT3334747 T LT 3334747T
Authority
LT
Lithuania
Prior art keywords
antigen
binding proteins
depth filtration
charged depth
charged
Prior art date
Application number
LTEPPCT/US2016/046929T
Other languages
English (en)
Inventor
Hai HOANG
Rafael Gonzalez
Junfen MA
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56802689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3334747(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of LT3334747T publication Critical patent/LT3334747T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G01N27/44791—Microapparatus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEPPCT/US2016/046929T 2015-08-13 2016-08-12 Įkrautas giluminis antigeną surišančio baltymo filtravimas LT3334747T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562204831P 2015-08-13 2015-08-13
PCT/US2016/046929 WO2017027861A1 (en) 2015-08-13 2016-08-12 Charged depth filtration of antigen-binding proteins

Publications (1)

Publication Number Publication Date
LT3334747T true LT3334747T (lt) 2023-12-27

Family

ID=56802689

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2016/046929T LT3334747T (lt) 2015-08-13 2016-08-12 Įkrautas giluminis antigeną surišančio baltymo filtravimas

Country Status (15)

Country Link
US (2) US11098079B2 (lt)
EP (2) EP3334747B1 (lt)
JP (1) JP6889149B2 (lt)
DK (1) DK3334747T5 (lt)
ES (1) ES2964640T3 (lt)
FI (2) FI4209499T3 (lt)
HR (1) HRP20231544T1 (lt)
HU (1) HUE064252T2 (lt)
LT (1) LT3334747T (lt)
MA (1) MA42613A (lt)
PL (1) PL3334747T3 (lt)
PT (1) PT3334747T (lt)
SG (1) SG10202101105XA (lt)
SI (1) SI3334747T1 (lt)
WO (1) WO2017027861A1 (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
LT3334747T (lt) 2015-08-13 2023-12-27 Amgen Inc. Įkrautas giluminis antigeną surišančio baltymo filtravimas
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
CN107973487B (zh) * 2017-11-14 2021-03-02 东华大学 一种染整废水层级处理工艺及装置
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
MX2022008442A (es) * 2020-01-15 2022-08-02 Hoffmann La Roche Metodos para disminuir impurezas de procesos de manufacturacion de proteinas recombinantes.
CN111410688A (zh) * 2020-03-13 2020-07-14 苏州智享众创孵化管理有限公司 一种提高双特异性抗体纯度的分离纯化方法
AU2021287998A1 (en) 2020-06-11 2023-02-02 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5237054A (en) 1987-02-20 1993-08-17 Akzo Pharma Stabilized aqueous composition containing antibodies
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
JP3095175B2 (ja) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
WO1996004925A1 (en) 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
AUPQ599700A0 (en) 2000-03-03 2000-03-23 Super Internet Site System Pty Ltd On-line geographical directory
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1385882B9 (en) 2001-05-11 2009-08-12 Amgen, Inc. Peptides and related molecules that bind to tall-1
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
EP2270052B8 (en) 2001-06-26 2018-05-02 Amgen Inc. Antibodies to OPGL
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
JP4359503B2 (ja) 2001-08-23 2009-11-04 ゲンマブ エー／エス インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
WO2003066669A2 (en) 2002-02-04 2003-08-14 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
NZ566539A (en) 2002-09-06 2010-01-29 Medarex Inc Therapeutic human anti-IL-1R1 monoclonal antibody
US7335743B2 (en) 2002-10-16 2008-02-26 Amgen Inc. Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
DK3284753T3 (da) 2002-10-17 2021-07-05 Genmab As Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
KR20140004805A (ko) 2002-12-20 2014-01-13 암겐 인코포레이티드 미오스타틴을 저해하는 결합제
ATE480567T1 (de) 2003-04-04 2010-09-15 Genentech Inc Hochkonzentrierter antikörper und proteinformulierungen
US7157276B2 (en) 2003-06-20 2007-01-02 Biogen Idec Inc. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
ES2392954T3 (es) 2003-07-15 2012-12-17 Amgen Inc. Anticuerpos neutralizantes anti-NGF humanos como inhibidores selectivos de la ruta de NGF
EP1694360B1 (en) 2003-11-04 2010-08-04 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
JP4931597B2 (ja) 2003-11-07 2012-05-16 イミュネックス・コーポレーション インターロイキン−４受容体を結合する抗体
WO2005063291A1 (ja) 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
SG162788A1 (en) 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
TW200801039A (en) 2005-09-15 2008-01-01 Wyeth Corp Separation methods
US20080132688A1 (en) * 2006-09-22 2008-06-05 Amgen Inc. Methods for Removing Viral Contaminants During Protein Purification
EP2089431A4 (en) * 2006-10-19 2010-03-17 Tolerx Inc METHOD AND COMPOSITIONS FOR EFFICIENT REMOVAL OF PROTEIN A FROM BINDING MOLECULE PREPARATION
KR101643514B1 (ko) 2007-07-09 2016-07-27 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
ES2774337T3 (es) 2008-01-07 2020-07-20 Amgen Inc Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
DE102008037678A1 (de) 2008-08-14 2010-02-25 Sartorius Stedim Biotech Gmbh Tiefenfilterschicht mit anorganischem Schichtdoppelhydroxid
JP5808249B2 (ja) 2008-10-20 2015-11-10 アッヴィ・インコーポレイテッド プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製
ES2551854T3 (es) * 2009-04-30 2015-11-24 Ablynx N.V. Procedimiento para la producción de anticuerpos de dominio
WO2011049798A1 (en) 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
EP3037104B1 (en) 2009-10-20 2020-05-27 AbbVie Inc. Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
WO2011140405A1 (en) * 2010-05-07 2011-11-10 Millipore Corporation Enhanced clarification media
EP2571892A2 (en) 2010-05-18 2013-03-27 AbbVie Inc. Apparatus and process of purification of proteins
EP2627425A4 (en) 2010-10-11 2014-11-05 Abbvie Inc METHODS OF PURIFYING PROTEINS
KR20130140010A (ko) 2010-10-20 2013-12-23 메디뮨 엘엘씨 봉입체의 가공처리 방법
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
US20130012689A1 (en) 2011-07-08 2013-01-10 Emd Millipore Corporation Depth Filters For Disposable Biotechnological Processes
FR2977893B1 (fr) 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
AU2012290004B2 (en) 2011-08-02 2014-11-27 Takeda Pharmaceutical Company Limited Systems and methods to increase protein yield from recombinant manufacturing processes
US9096648B2 (en) 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
US10344050B2 (en) * 2011-10-27 2019-07-09 Genmab A/S Production of heterodimeric proteins
RU2648999C2 (ru) 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
US20140010820A1 (en) 2012-05-21 2014-01-09 Abbvie, Inc. Novel purification of non-human antibodies using protein a affinity chromatography
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
EP2682168A1 (en) 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
CN110950955A (zh) * 2012-12-20 2020-04-03 米迪缪尼有限公司 生产免疫偶联物的方法
TWI670279B (zh) 2013-03-15 2019-09-01 美商艾爾德生物製藥股份有限公司 抗體純化及純度監測
US10174076B2 (en) 2013-06-04 2019-01-08 Agency For Science, Technology And Research Protein purification process
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
GB201318840D0 (en) 2013-10-24 2013-12-11 Univ Leeds Method and device for protein preparation
EP3066121A1 (en) * 2013-11-07 2016-09-14 AbbVie Inc. Isolation and purification of dvd-igs
CN106164086A (zh) 2014-02-27 2016-11-23 新加坡科技研究局 抗体纯化方法
WO2015142777A1 (en) 2014-03-17 2015-09-24 Regeneron Pharmaceuticals, Inc. Clarification of mammalian cell culture
US20170183376A1 (en) 2014-06-24 2017-06-29 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
WO2016106291A1 (en) 2014-12-22 2016-06-30 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
LT3334747T (lt) 2015-08-13 2023-12-27 Amgen Inc. Įkrautas giluminis antigeną surišančio baltymo filtravimas

Also Published As

Publication number Publication date
EP3334747B1 (en) 2023-09-27
US20210363180A1 (en) 2021-11-25
US20180230180A1 (en) 2018-08-16
PL3334747T3 (pl) 2024-04-02
HUE064252T2 (hu) 2024-02-28
EP3334747A1 (en) 2018-06-20
EP4209499B1 (en) 2024-08-07
WO2017027861A1 (en) 2017-02-16
FI3334747T3 (fi) 2023-11-30
EP4209499A1 (en) 2023-07-12
SG10202101105XA (en) 2021-03-30
JP2018526357A (ja) 2018-09-13
JP6889149B2 (ja) 2021-06-18
HRP20231544T1 (hr) 2024-03-15
MA42613A (fr) 2018-06-20
DK3334747T3 (da) 2023-12-11
SI3334747T1 (sl) 2024-02-29
FI4209499T3 (fi) 2024-11-05
PT3334747T (pt) 2023-12-12
US11098079B2 (en) 2021-08-24
DK3334747T5 (da) 2024-10-07
ES2964640T3 (es) 2024-04-08

Similar Documents

Publication Publication Date Title
IL285366A (en) Multi-specific antigen-binding proteins
IL263690A (en) Purification of multispecific antibodies
HUE058755T2 (hu) Anti-tigit antigénkötõ proteinek és felhasználásuk módszerei
HK1231400A1 (zh) 蛋白質的選擇性還原
SG10202101105XA (en) Charged depth filtration of antigen-binding proteins
IL251125B (en) Methods for the separation of gemcitabine-phosphate diastereoisomers
ZA201808524B (en) Methods of affecting separation
IL248697A0 (en) Methods for purifying antibodies
GB201604627D0 (en) Improved method of FT-IMS
IL272670A (en) Preparation of micro-electrodes
SG10202007893TA (en) Methods of immunotherapy
IL252712A0 (en) Method for protein production
IL248694B (en) Nanoencapsulation of antigen binding molecules
HK1223624A1 (zh) 替諾福韋的固體形式
GB201609314D0 (en) Methods of forming compounds
TWM533475U (en) Improved structure of filter
GB201508443D0 (en) Methods of identifying USP-binding compounds